Evidence map›Paper›PMID 41385773›Full record

ReviewMagyar onkologia2025

[Diagnostics and therapy of gastroenterological side effects of immune checkpoint inhibitor therapy].

Benjámin György Klément, Kamilla Németh, Borbála Székely, Ádám Tarpay

Abstract readReviewEnglish Abstract
In one paragraph

Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benjámin György KlémentMellkasi és Hasüregi Daganatok és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. klement.gyorgy@oncol.hu.
Kamilla NémethDaganatpatológiai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
Borbála SzékelyMellkasi és Hasüregi Daganatok és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. klement.gyorgy@oncol.hu.
Ádám TarpayInvazív Gasztroenterológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the increasing use of immunotherapy, numerous gastroenterological side effects may occur, significantly impacting patients' quality of life and potentially leading to life-threatening complications. The most common adverse effects include diarrhea, colitis, hepatitis, pancreatitis, but other gastrointestinal manifestations such as those affecting the upper digestive tract and celiac disease have also been reported. Rapid recognition and intervention are crucial for improving patient outcomes, with corticosteroids being the primary treatment option, and various biological therapies are available depending on the specific side effect. This article provides a detailed analysis of the diagnostic and therapeutic approaches for common side effects, facilitating the exclusion of other etiologies and enabling effective treatment planning.

Indexed as

Antineoplastic Agents, ImmunologicalGastrointestinal DiseasesImmune Checkpoint InhibitorsImmunotherapyNeoplasmsCeliac DiseaseColitisDiarrheaHepatitisHumansPancreatitisQuality of LifeAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Identifiers

PMID41385773
PMCPMC12701784

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.